Incyte appointed Bill Meury as its new CEO, replacing Hervé Hoppenot after an 11-year tenure marked by growth of the company’s flagship product Jakafi and expanded global presence. Meury, known for leading successful biotech acquisitions including Anthos Therapeutics and Karuna Therapeutics, arrives amid efforts to diversify Incyte's pipeline as key patents approach expiration. Hoppenot will stay on as a director through end of year to support transition. Board leadership also shifted with Julian Baker becoming chair.